CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta and Tecartus in treating several types of blood cancers.

In 2012, there were only 12 clinical trials investing CAR-T cell therapy products. Today, that number has surged to 514. Between 2017 and 2020, three CAR-T products reached the market and this number is projected to reach double digits by 2024.

The earliest approvals, Kymriah and Yescarta, have been commercially available since 2017 and 2018, respectively, and have been infused into nearly a half million patients worldwide. In July 2020, the U.S. FDA approved a third CAR-T cell therapy, Kite Pharma’s brexucabtagene autoleucel, sold under the brand name Tecartus.

All the three of the approved CAR-T products and nearly 75% of the ongoing clinical trials take an autologous treatment approach. Autologous (self-derived) CAR-T cells are expensive to produce because they are manufactured on a patient-by-patient basis. Thus, CAR-T therapies are most often recommended for the end-stage patients who have exhausted other treatment options. 

To accelerate the adoption of CAR-T cell therapies, a number of CAR-T players have started to use efficient gene-transfer tools to impregnate the T cells with CARs. There are numerous examples of partnerships to develop CRISPR and electroporation technologies to modify the T cells. Some companies are also using “on-off” switches that can turn off CAR-T cells to prevent toxicity.

Unfortunately, the goal of achieving CAR-T success against solid tumors remains elusive so far, with clinical trials demonstrating a severely limited response.

Historic approvals of Kymriah, Yescarta and Tecartus demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm.

With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

Be Great,

BioInformant Team

p.s. Act fast, because this offer expires soon.